Sarepta Therapeutics/$SRPT
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
- Ticker
- $SRPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 835
- Headquarters
- Cambridge, United States
- Website
- www.sarepta.com
SRPT Metrics
BasicAdvanced
$2.2B
-
-$1.32
0.20
-
Price and volume
Market cap
$2.2B
Beta
0.2
52-week high
$25.32
52-week low
$14.68
Average daily volume
3M
Financial strength
Current ratio
4.422
Quick ratio
2.44
Long term debt to equity
68.455
Total debt to equity
69.539
Interest coverage (TTM)
-0.87%
Profitability
EBITDA (TTM)
-17.533
Gross margin (TTM)
-17.30%
Net profit margin (TTM)
-6.92%
Operating margin (TTM)
-3.15%
Effective tax rate (TTM)
-4.43%
Revenue per employee (TTM)
$2,360,000
Management effectiveness
Return on assets (TTM)
-1.13%
Return on equity (TTM)
-9.48%
Valuation
Price to revenue (TTM)
1.098
Price to book
1.44
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
28.905
Free cash flow yield (TTM)
3.46%
Free cash flow per share (TTM)
0.722
Growth
Revenue change (TTM)
-20.44%
Earnings per share change (TTM)
119.75%
3-year revenue growth (CAGR)
25.31%
10-year revenue growth (CAGR)
108.81%
3-year earnings per share growth (CAGR)
-49.64%
10-year earnings per share growth (CAGR)
-13.09%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Business Wire5 days ago
Sarepta Therapeutics Q2 Earnings Call Highlights
MarketBeat3 weeks ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.